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Abstract: Lippia citriodora ethanolic extract (VEE) and verbascoside (Vs), a phenypropanoid glycoside,
have been demonstrated to exert relaxant and anxiolytic properties. However, the molecular
mechanisms behind their effects are still unclear. In this work, we studied the effects and action
mechanisms of VEE and Vs in vivo and in vitro, on human neurotypic SH-SY5Y cells.TST was
conducted on mice treated orally with VEE (25, 50 and 100 mg/Kg), Vs (2.5 and 5 mg/Kg), Bupropion
(20 mg/Kg) and Milli-Q water. Higher dose of VEE-treated mice showed an increase of immobility
time compared to control groups, indicating an induction of relaxation. This effect was found to
be induced by regulation of genes playing key roles in calcium homeostasis (calcium channels),
cyclic AMP (cAMP) production and energy metabolism. On the other hand, low doses of VEE and
Vs showed an antidepressant-like effect and was confirmed by serotonin, noradrenalin, dopamine
and BDNF expressions. Finally, VEE and Vsenhancedcell viability, mitochondrial activity and
calcium uptake in vitro confirming in vivo findings. Our results showed induction of relaxation and
antidepressant-like effects depending on the administered dose of VEE and Vs, through modulation
of cAMP and calcium.
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1. Introduction
The Verbenaceae, commonly known as the verbena or vervain family, is composed of 35 genera
containing around 1200 species [1]. They have been used for centuries as medicinal plants due to
their beneficial effects to cure several ailments. One of the most important genera is Lippia, consisting
of200 species exerting interesting biological activities [2]. Lippia citriodora K., also referred to as
Aloysiatriphylla(L’Herit.), is commonly named lemon verbena, vervain or Louisa (Arabic). This species
is native to South America and has been cultivated in Europe and North Africa mainly in Morocco [3].
All over Morocco, the plant is used as relaxant and sedative [4]. The herbal tea is traditionally used to
alleviate insomnia and restlessness in adults as well as babies [5]. Furthermore, it has been used for its
anti-inflammatory, antioxidant, antispasmodic effects and also used as a remedy for gastrointestinal
disorders [2]. Recent studies have confirmed the antioxidant and spasmolytic activities of the infusion
prepared of lemon verbena [6,7]. Verbena aqueous extract given to rats has proven the hypnotic effect
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of the plant by promoting sleep [8]. Polyphenols extracted from lemon verbena reduced the obesity
burden and restored the mitochondrial activity through AMPK-dependent pathways [9].
Verbascoside (Vs), a major phenypropanoid glycoside, is the most abundant polyphenol in lemon
verbena tea and its yield is reported to be around 3.94% (w/w dry weight of leaves) [10]. Vs contained in
Buddlejia davidii and Lippia multiflora has already been proven to possess an antioxidant activity [11,12].
Vs has also shown an anti-inflammatory effect in vitro on macrophages and THP-1 cells [13,14].
Furthermore, Vs has been reported to exert an antimicrobial activity against Staphylococcus aureus
and a neuroprotective effect, in vitro, on 1-methyl-4-phenylpyridinum ion-induced toxicity using
PC12 cells [15,16]. Interestingly, intraperitoneal administration of Vs and lemon verbena aqueous and
ethanolic extracts to mice promoted sleep and induced muscle relaxation, alongside alleviation of
anxiety [17]. In addition to Vs, hastatoside (Hs) and verbenalin (Vn) are two abundant iridoids in
verbena extract and have been proved to possess sleep-promoting effect [18]. To date, very little is
known about the molecular mechanism by which lemon verbena or its compounds induce relaxation
and act as anti-anxiety remedies.
In the present study, we investigated the effect of lemon verbena and Vs in mice and elucidated
the molecular mechanisms underlying their effects in brain. Interestingly, the transcriptomic analysis
in vivo showed regulation of genes implicated in activation of the mitochondrial function. Therefore,
to confirm this finding we evaluated, in vitro, the effect of VEE and Vs on cells’ ATP production
using SH-SY5Y, a Human neurotypic cell line. Also, we assessed the toxicity of VEE, Vs, Hs, and Vn,
in addition to neuroprotective effect on dexamethasone (Dex) neurotoxicity.
2. Results
2.1. Effect of VEE and Its Compounds on SH-SY5Y Cells’Viability
We performed the MTT assay to assess the effect of VEE on cell viability. We treated the cells
with different concentrations of the extract which were 0.5, 1, 2.5 and 5 µg/mL of VEE. As shown in
Figure 1A, all VEE concentrations increased cell viability significantly in a dose-dependent manner,
with a higher value of 126.68 ± 7.81% at 2.5 µg/mL. The chemical analysis of various Verbenaceae
plants, including Lippia citriodora and Verbena officinalis, showed a high abundance in Vs, also called
acteoside, which is a phenylpropanoid glycoside [19–24]. In our study, we evaluated the cell viability
of SH-SY5Y cells treated with 5, 50 and 100 µM of Vs, Hs and Vn. The results in Figure 1C show an
increase of viable cells in a dose-dependent manner attaining 134.8 ± 3.8% at 100 µM in case of Vs.
On the other hand, Hs and Vn decreased the cell viability significantly (Figure 1C). From these results,
we selected Vs to be evaluated for its neuroprotective and energy metabolism effects.
In order to evaluate the neuroprotective activity, we used dexamethasone (Dex) as neurotoxic agent.
VEE treatment protected SH-SY5Y cells fromDex toxicity with higher increase at 5 µg/mL (42.82% cell
viability) (Figure 1B). Interestingly, cells co-treated with Vs and Dex showed an enhancement of
cell viability by more than 30% compared to Dex-treated cells (Figure 1D). These data indicate
neuroprotective effect exerted by VEE and Vs.
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Figure 1. Relative cell viability of SH-SY5Y cells (A) treated with Lippiacitriodora ethanolic extract 
(VEE) at doses of 0.5, 1, 2.5 and 5 µg/mL, (B) co-treated with VEE and dexamethasone(Dex) (50 µM), 
(C) treated with verbascoside(Vs), hastatoside(Hs), and verbenalin(Vn) (5, 50 and 100 µM) and (D) 
co-treated with Vs and Dex (50 µM). Results were expressed in mean of cell viability ± SD.* P < 0.05; 
** P < 0.001; *** P < 0.0001 compared with negative control group. # P < 0.05; ## P < 0.001; ### P < 
0.0001 compared to Dex-treated group. 
2.2. Effect of VEE on the Immobility Time of Mice 
The tail suspension test (TST) was used to assess the antidepressant-like effect of VEE 100 
mg/Kg compared to the control groups. Normally, drugs having an antidepressant effect decrease 
the immobility time of mice. In the present study, bupropion was used as a positive control, known 
for its antidepressant property. Bupropion-treated mice showed a decrease of immobility time on 
the 4th day of TST to 39.37 s compared to the initial test performed on the 1st day with a value of 42.52 
s, resulting of the drug’s effect (Figure 2). As for the negative control group, the mice were fed with 
Milli-Q water and showed a gradual increase of immobility time to day 7 with 114.4 s compared to 
the initial test with a time of 35.48 s, proving an induction of depression on mice by TST, leading the 
animals to lack the desire to rectify themselves (Figure 2). 
Interestingly, 100 mg/Kg body weight VEE-treated mice showed a highly significant increase of 
immobility time compared to negative and positive controls starting from day 4 of the test with 
202.64 s, which gradually decreased to attain 177.63 s on the 7th day (Figure 2).The low immobility 
time of the depressant mice receiving only water compared the VEE-treated mice suggested that the 
effect observed was not a result of the stress induced by TST, but because of the induction of 
relaxation by VEE, which is a unique effect of VEE. 
Figure 1. Relative cell viability of SH-SY5Y cells (A) treated with Lippiacitriodora ethanolic extract (VEE)
at doses of 0.5, 1, 2.5 and 5 µg/mL, (B) co-treated with VEE and dexamethasone(Dex) (50 µM), (C) treated
with verbascoside(Vs), hastatoside(Hs), and verbenalin(Vn) (5, 50 and 100 µM) and (D) co-treated with
Vs and Dex (50 µM). Results were expressed in mean of cell viability ± SD. * P < 0.05; ** P < 0.001;
*** P < 0.0001 compared with negative control group. # P < 0.05; ## P < 0.001; ### P < 0.0001 compared
to Dex-treated group.
2.2. Effect of VEE on the Immobility Time of Mice
The tail suspension test (TST) was used to assess the antidepressant-like effect of VEE 100 mg/Kg
compared to the control groups. Normally, drugs having an antidepressant effect decrease the
immobility time of mice. In the present study, bupropion was used as a positive control, known for its
antidepressant property. Bupropion-treated mice showed a decrease of immobility time on the 4th day
of TST to 39.37 s compared to the initial test performed on the 1st day with a value of 42.52 s, resulting
of the drug’s effect (Figure 2). As for the negative control group, the mice were fed with Milli-Q water
and showed a gradual increase of immobility time to day 7 with 114.4 s compared to the initial test
with a time of 35.48 s, proving an induction of depression on mice by TST, leading the animals to lack
the desire to rectify themselves (Figure 2).
Interestingly, 100 mg/Kg body weight VEE-treated mice showed a highly significant increase
of immobility time compared to negative and positive controls starting from day 4 of the test with
202.64 s, which gradually decreased to attain 177.63 s on the 7t day (Figure 2).The low immobility
time of the depressant mice receiving only water compared the VEE-treated mice suggested that the
effect observed was not a result of the stress induced by TST, but because of the induction of relaxation
by VEE, which is a unique effect of VEE.
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Figure 2. Effect of the oral administration of VEE (100 mg/Kg) and bupropion (20 mg/Kg) on mice 
immobility times in tail suspension test compared to the control (water 10 mL/Kg, p.o.). Results were 
expressed in mean of immobility time ± SD.* P < 0.05; ** P < 0.001 compared with Control group. 
2.3. Elucidation of the Genes Regulated by VEE Treatment 
To determine the molecular mechanism underlying the effect of VEE on immobility time, we 
analyzed the mice brains using DNA microarray to detect the transcriptomic changes. The analysis 
of the data revealed the up-regulation of 62 genes with a fold-change higher than 1.2, while 256 
others were down-regulated below 0.65 fold-change. After annotating the genes, they were clustered 
in order to study their interactions and the pathways they are implicated in. Bupropion and VEE 
affected interesting pathways controlling the neuronal proliferation, spatial learning and memory, 
long-term potentiation and depression, inflammation and reactive oxygen species (ROS) production 
(Table 1). Interestingly, VEE treatment regulated genes such as Adenylate cyclase (Ac) implicated in 
the production of cyclic-Adenosine monophosphate (cAMP). It up-regulated the expression of genes 
implicated in calcium signaling including Inositol 1,4,5-trisphosphate receptor type 2 (Itpr2), Protein 
kinase C (Pkc) and Calcium channel voltage-dependent L type alpha 1C subunit (Cacna1c)[25,26].VEE 
treatment increased the expression of Calcium/ calmodulin dependent protein kinase IV (CamkIV), one of 
the genes stimulating mitochondrial biogenesis [27]. The expression of cGMP-dependent protein kinase 
(Prkg1) was affected by verbena treatment, which results in the induction of muscle relaxation [28]. 
Also, 5 hydroxytryptamine (serotonin) receptor 4 (Htr4) involved in neurotransmitters production was 
enhanced, alongside with AdenosineA2a receptor (Adora2), responsible of the development of several 
neurodegenerative diseases [29–31]. VEE enhanced the expression of Dopamine receptor D1 
(Drd1),implicated in activation of Ac [32].  
As shown in Table 1, out of the all sets of genes, three were highly expressed in the case of 
VEE-treated mice, which are Gelsolin (Gsn), Transthyretin (Ttr) and Calcium/ calmodulin-dependent 
protein kinase 2 inhibitor 1 (Camk2n1). Their expressions were increased 5.26, 3.72 and 2.19 fold, 
respectively. Recent studies showed a positive correlation between mitochondrial activity and 
expression of Ttr and Gsn [33,34]. As for Camk2n1, it has been shown to possess a role in controlling 
cell proliferation [35]. 
VEE treatment decreased the expression of melanin-concentrating hormone receptor 1 (Mchr1) to a 
fold-change equal to 0.55, while bupropion did not affect its transcription level. The 
down-regulation of this gene was found to enhance the metabolism [36], which implicates an 
activation of mitochondria. Also, Mchr1 antagonist exerted an anti-depressant effect [37]. 
The pro-melatonin-concentrating hormone (Pmch) was drastically down-regulated (Table 1). It has 
been previously shown to exert a role in energy metabolism [38]. 
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2.3. Elucidation of the Genes Regulated by VEE Treatment
To determine the molecular mechanism underlying the effect of VEE on immobility time, we
analyzed the mice brains using DNA microarray to detect the transcriptomic changes. The analysis of
the data revealed the up-regulation of 62 genes with a fold-change higher than 1.2, while 256 others
were down-regulated below 0.65 fold-change. After annotating the genes, they were clustered in
order to study their interactions and the pathways they are implicated in. Bupropion and VEE
affected interesting pathways controlling the neuronal proliferation, spatial learning and memory,
long-term potentiation and depression, inflammation and reactive oxygen species (ROS) production
(Table 1). Interestingly, VEE treatment regulated genes such as Adenylate cyclase (Ac) implicated
in the production of cyclic-Adenosine monophosphate (cAMP). It up-regulated the expression of
genes implicated in calcium signaling including Inositol 1,4,5-trisphosphate receptor type 2 (Itpr2),
Protein kinase C (Pkc) and Calcium channel voltage-dependent L type alpha 1C subunit (Cacna1c) [25,26]. VEE
treatment increased the expression of Calcium/calmodulin dependent protein kinase IV (CamkIV), one of
the genes stimulating mitochondrial biogenesis [27]. The expression of cGMP-dependent protein kinase
(Prkg1) was affected by verbena treatment, which results in the induction of muscle relaxation [28].
Also, 5 hydroxytryptamine (serotonin) receptor 4 (Htr4) involved in neurotransmitters production was
enhanced, alongside with AdenosineA2a receptor (Adora2), responsible of the development of several
neurodegenerative diseases [29–31]. VEE enhanced the expression of Dopamine receptor D1 (Drd1),
implicated in activation of Ac [32].
As shown in Table 1, out of the all sets of genes, three were highly expressed in the case of
VEE-treated mice, which are Gelsolin (Gsn), Transthyretin (Ttr) and Calcium/calmodulin-dependent protein
kinase 2 inhibitor 1 (Camk2n1). Their expressions were increased 5.26, 3.72 and 2.19 fold, respectively.
Recent studies showed a positive correlation between mitochondrial activity and expression of Ttr and
Gsn [33,34]. As for Camk2n1, it has been shown to possess a role in controlling cell proliferation [35].
VEE treatment decreased the expression of melanin-concentrating hormone receptor 1 (Mchr1) to a
fold-change equal to 0.55, while bupropion did not affect its transcription level. The down-regulation
of this gene was found to enhance the metabolism [36], which implicates an activation of mitochondria.
Also, Mchr1 antagonist exerted an anti-depressant effect [37].
The pro-melatonin-concentrating hormone (Pmch) was drastically down-regulated (Table 1). It has
been previously shown to exert a role in energy metabolism [38].
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Table 1. Genes regulated by VEE involved in induction of relaxation and the activation of energy
metabolism. The ratios were calculated using the data of mice receiving water as reference.
Gene ID Gene Name VerbenaRatio
Bupropion
Ratio Function
Gsn Gelsolin 5.26 1.54 Amyloid beta peptides
aggregation [33,39]Ttr Transthyretin 3.72 3.91
Camk2n1 Calcium/calmodulin-dependentprotein kinase 2 inhibitor 1 2.19 1.03 Tumor suppressor [35]
CaMK4 calcium/calmodulin-dependentprotein kinase IV 1.46 1.20 Long-term memory [40]
Cacna1c Calcium channel, voltage-dependent,L type, alpha 1C subunit 1.45 1.07 Cytosolic calcium content [26]
Pkc Protein kinase c 1.45 0.98 Adenylate cyclase
activation [32,41]Drd1 Dopamine receptor 1 1.43 1.07
Adora2 Adenosine A2a receptor 1.34 1.1
Cyclic-Adenosine
monophosphate (cAMP)
production [42]
Htr4 5 hydroxytryptamine (serotonin)receptor 4 1.34 1.25
Modulation of
neurotransmitter release [29]
Itpr2 Inositol 1,4,5-trisphosphatereceptor type 2 1.30 1.22
Intracellular calcium
release [25]
Ac Adenylate cyclase 1.28 0.85 Production of cAMP [43]
Prkg1 cGMP-dependent protein kinase 1 1.25 1.32 Induction of relaxation [28]
Mchr1 melanin-concentratinghormone receptor 0.55 1.01
Inhibition of cAMP
accumulation [44]
Pmch pro-melanin-concentrating hormone 0.12 0.12 Melanin-concentratinghormone activity [45]
2.4. Validation of Expressions of Gsn, Ttr, Camk2n1 and Itpr2
The microarray analysis of brains collected from mice treated with 100 mg/Kg of VEE showed
up-regulation of genes implicated in mitochondrial activity, with fold-changes higher than 2. These
genes are Gsn, Ttr, and Camk2n1. Their up-regulations were confirmed and represented in relative gene
expression, with the negative control expression as reference. Expressions of Gsn, Ttr, and Camk2n1
were increased in the case of VEE-treated mice by 305% (relative gene expression), 115% and 110%,
respectively (Figure 3A–C). The Camk2n1 is an inhibitor that alters the transportation of Ca2+, responsible
of the control of the intracellular amount of this ion to avoid its side effects.
Itpr2 is responsible of intracellular calcium release. This gene was up-regulated by VEE treatment.
Its expression was confirmed and showed an enhancement of 160% in VEE-treated mice compared to
the control group. The effect of bupropion was not significant compared to VEE, with an increase of
19% (Figure 3D).
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Figure 3. Validation of the expression of genes regulated by VEE treatment (100 mg/Kg) which are 
(A) Ttr, (B) Camk2n1, (C) Gsn, and (D) Itpr2. Results were expressed in relative gene expression ± SD.
* P < 0.05; ** P < 0.001; *** P < 0.0001 compared with negative control group. # P < 0.05; ## P < 0.001; ###
P < 0.0001 compared to bupropion-treated group.
2.5. Antidepressant Effect of Low Doses of VEE and Vs 
The control group showed higher immobility time compared to other treatments for 7 days of 
testing (Figure 4A). The immobility recorded on the first day was 63.81 s for the control, which 
increased to reach 84.33s on day 7. This increase proved induction of depression in mice. Bupropion 
treated mice scored an immobility time of 16.96 s on the first day and decreased to 1.56 s on the last 
day of the test, proving the antidepressant effect of bupropion. Results obtained on first day showed 
a significant difference between the control group and Vs and VEE at a dose of 25 mg/Kg. On the 
second day, VEE and Vs treatments decreased the immobility time and the scores were statistically 
comparable to the bupropion treated group, while the difference was highly significant compared to 
the control. Similar results were observed for the rest of the test, except on day 3 and 5 where the 
difference was not significant between the control group and the 25 mg/Kg VEE treated animals. 
Figure 3. Validation of the expression of genes regulated by VEE treatment (100 mg/Kg) which are
(A) Ttr, (B) Camk2n1, (C) Gsn, and (D) Itpr2. Results were expressed in relative gene expression ± SD.
* P < 0.05; ** P < 0.001; *** P < 0.0001 compared with negative control group. # P < 0.05; ## P < 0.001;
### P < 0.0001 compared to bupropion-treated group.
2.5. Antidepressant Effect of Low Doses of VEE and Vs
The control group showed higher immobility time compared to other treatments for 7 days
of testing (Figure 4A). T e immobility recorded on the first day was 63.81 s for the control, which
increased to ach 84.33s on day 7. This incr ase proved induction of depre si n in mice. Bupropion
treated mice scored an immobility time of 16.96 s n the first day an decreased to 1.56 s on the last
day of the te t, provi g the antidepressant effect of bupropion. Results obtain on first day s owed
a significant differe ce b tween th co trol group and Vs and VEE at a dose of 25 mg/Kg. On the
seco d day, VEE and Vs treatments decreased the immobility time and the sc res were statistically
comparable to the bupropion tr ated group, whil the difference was hig ly significant compared to
the control. Similar results were observed for the r st of the t st, except on day 3 d 5 where the
difference was not significant b tween the c ntrol group and the 25 mg/Kg VEE treate animals.
For decades, depression has b en ass ciated with levels of monoamines and catechol mines
in the system [46]. Depressive patients have been found to present Sert and NA (norepinephrine)
deficiency [47,48]. To confirm the antidepressant effect of the treatments on mice we quantified the
amounts of Sert and NA in mice brains. The results showed a low concentration of Sert and NA
for control group with an amount of 18 and 171 ng/100 mg total proteins, respectively (Figure 4B,C).
Bupropion increased significantly Sert level by 61% compared to control group. A similar effect
was observed in case of mice treated with VEE 25 and 50 mg/Kg and Vs 2.5 and 5 mg/Kg showing
improvement of 57.90%, 67.05%, 69.19%and 61.04% total proteins, respectively. An enhancement of
19% was observed in NA level in case of bupropion treated mice. Also, the other treatments increased
NA concentration with a higher rate of 19.35% for Vs 2.5 mg/Kg treated group.
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Figure 4. Effect of the oral administration of VEE (25 and 50 mg/Kg), Vs (2.5 and 5 mg/Kg) and 
bupropion (20 mg/Kg) on (A) mice immobility times in tail suspension test compared to the control 
(water 10 mL/Kg, p.o.) and their respective expression levels of (B) serotonin, (C) noradrenaline (D) 
dopamine and (E) BDNF. Results were expressed in mean of immobility time (s) and protein level ± 
SD.* P < 0.05; **P < 0.001 and *** P < 0.0001 compared with Control group. 
For decades, depression has been associated with levels of monoamines and catecholamines in 
the system [46]. Depressive patients have been found to present Sert and NA (norepinephrine) 
deficiency [47,48]. To confirm the antidepressant effect of the treatments on mice we quantified the 
amounts of Sert and NA in mice brains. The results showed a low concentration of Sert and NA for 
control group with an amount of 18 and 171 ng/ 100 mg total proteins, respectively (Figure 4B,C). 
Bupropion increased significantly Sert level by 61% compared to control group. A similar effect was 
observed in case of mice treated with VEE 25 and 50 mg/Kg and Vs 2.5 and 5 mg/Kg showing 
improvement of 57.90%, 67.05%, 69.19%and 61.04% total proteins, respectively. An enhancement of 
19% was observed in NA level in case of bupropion treated mice. Also, the other treatments 
increased NA concentration with a higher rate of 19.35% for Vs 2.5 mg/Kg treated group. 
One of the important targets of antidepressants is the dopaminergic system. We evaluated the 
effect of our treatments on dopamine levels in mice brains. Bupropion showed an increase of 
dopamine content by 26% (Figure 4D). The highest dopamine concentration, with an increase of 
34.45%, was observed in mice treated with 25 mg/Kg of VEE. The lowest dopamine enhancement 
(21.21%) was obtained for mice treated with 5 mg/Kg of Vs. 
Furthermore, we evaluated the concentration of BDNF, which is one of the markers of 
depression. Our findings showed an increase of BDNF levels in all treatments. Bupropion enhanced 
BDNF expression by 64.34% (Figure 4E). Interestingly, VEE at 25 mg/Kg and Vs at 2.5 and 5 mg/Kg 
were found to exert more substantial effect regarding BDNF level with an enhancement of 64.67%, 
76.36% and 69.26%. 
2.6. Evaluation of the Mitochondrial Activity of Cells Treated with VEE and Vs 
In order to measure the mitochondrial activity, we used the rhodamine 123 that stains the active 
mitochondria specifically. Both VEE and Vs induced mitochondrial activation of SH-SY5Y cells in a 
dose-dependent manner, with higher effect at lower concentrations. VEE at 0.5 µg/mL increased 
mitochondrial activity by 17% and its effect decreased to reach 9.37% for cells treated by 5 µg/mL 
(Figure 5A). Mitochondrial activity of cells treated with 5 µ M of Vs was 115% compared to control, 
while the higher concentration enhanced the function only by 3% (Figure 5B). These results 
implicated a stimulation of energy production of VEE and Vs treatments. 
The same concentrations of VEE and Vs were evaluated for their effect on energy generation by 
quantifying ATP level. As Figure 5C shows, VEE treatments were not effective on energy 
Figure 4. Effect of the oral a i i i f EE (25 and 50 mg/Kg), Vs (2.5 and 5 mg/Kg) and
bupropion (20 mg/Kg) on (A) ice i ilit ti s i tail suspension test compared to the control
(water 10 mL/Kg, p.o.) and their res ecti e ex ression levels of (B) serotonin, (C) noradrenaline (D)
dopamine and (E) BDNF. Results were expressed in mean of im obility time (s) and protein level ± SD.
* P < 0.05; ** P < 0.001 and *** P < 0.0001 compared with Control group.
One of the important targets of antidepressants is th d paminergic system. We ev luated the
effect of our treatments on dopamine levels in mice brains. Bupropion showed an increase of dopamine
content by 26% (Figure 4D). The highest dopamine concentration, with an increase of 34.45%, was
observed in mice treated with 25 mg/Kg of VEE. The lowest dopamine enhancement (21.21%) was
obtained for mice treated with 5 mg/Kg of Vs.
Furthermore, we evaluated the concentration of BDNF, which is one of the markers of depression.
Our findings showed an increase of BDNF levels in all treatments. Bupropion enhanced BDNF
expression by 64.34% (Figure 4E). Interestingly, VEE at 25 mg/Kg and Vs at 2.5 and 5 mg/Kg were
found to exert more substantial effect regarding BDNF level with an enhancement of 64.67%, 76.36%
and 69.26%.
2.6. Evaluation of the Mitochondrial Activity of Cells Treated with VEE and Vs
In order to measure the mitochondrial activity, we used the rhodamine 123 that stains the active
mitochondria specifically. Both VEE and Vs induced mitochondrial activation of SH-SY5Y cells in
a dose-dependent mann r, with higher effect at lower concentrations. VEE at 0.5 µg/ L increased
mitochondrial activity by 17% and its effect decreased to reach 9.37% for cells treated by 5 µg/mL
(Figure 5A). Mit chondrial activity of cells treated with 5 µM of Vs was 115% compare to control,
while the higher concentration enhanced the functio only by 3% (Figure 5B). Thes results implicated
a stimulation of energy production of VEE and Vs treatments.
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Figure 5. Evaluation of mitochondrial activity of SH-SY5Y cells treated with different concentrations
of (A) VE and (B) Vs. The intracellular ATP production of SH-SY5Y was as es ed in vitro using the
same concentrations of (C) VE and (D) Vs at 6, 12, 24, 48 and 72 h. Results were expres ed in mean
of relative mitochondrial activity or ATP production (%) ± SD. * P < 0.05; ** P < 0.001; *** P < 0.0001
compared with control cells treated with Opti-MEM.
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The same concentrations of VEE and Vs were evaluated for their effect on energy generation by
quantifying ATP level. As Figure 5C shows, VEE treatments were not effective on energy metabolism
at 6 h, but they show a highly significant increase after 12 h, with a maximum of 129.71 ± 2.73%.
The ATP content decreased in a time and dose-dependent manner to reach energy homeostasis
after 72 h. Treating the cells with Vs increased ATP production significantly after 12 h (Figure 5D),
which decreased gradually to attain the normal status at 72 h.These results proved the stimulation
mitochondria by VEE and Vs.
2.7. Effect of VEE and Vs on Intracellular Calcium Levels
Studies have shown a correlation between intracellular calcium uptake and mitochondrial
activation. Transcriptomic analysis showed regulation of genes involved in Ca2+ in cases of mice
treated with VEE. Here, we evaluated the effect of VEE and Vs on Ca2+ levels on SH-SY5Y. VEE
increased Ca2+ uptake after 30 min of treatment in concentration and time-dependent manner, with
higher effect at lower concentrations (Figure 6A). Accordingly, Vs showed similar effect on Ca2+ with
higher activity at lower doses (Figure 6B). These results proved the implication of Ca2+ in the observed
activities, with Vs being responsible for VEE effects.
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Figure 6. Evaluation of intracellular calcium levels of SH-SY5Y cells treated with different concentrations
of (A) VEE and (B) Vs for 1–180 min. Results were expressed as percentage of control cells treated with
Opti-MEM ± SD. * P < 0.05; ** P < 0.001; *** P < 0.0001 compared with control cells.
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3. Discussion
Lemon verbena is a medicinal plant exerting important biological activities such as antidepressant,
antioxidant, sleep-promoting and analgesic effects [24,49–51]. The molecular mechanisms underlying
these effects are still unknown.
The in vitro study showed an increase of cell viability of VEE-treated cells compared to the
non-treated cells, indicating an activation of cellular functionalities. Co-treatment of VEE and Dex
enhanced the cell viability significantly compared to the Dex-treated cells. To determine the compound
responsible for the effect observed, we treated the cells with the three most abundant compounds in
the extract, Vs, Hs and Vn. The viability was enhanced by Vs in comparison to the control, while Hs
and Vn were significantly decreased. The effect observed in the case of the extract is probably due to
Vs. Also, Vs was tested for its neuroprotective effect and was found to alleviate Dex toxicity by more
than 30%. These findings suggest that VEE and Vs have neuroprotective effects.
In the present work, we studied the effect of VEE on mice at the molecular level by analyzing
the expression of all genes. We used the TST to induce psychological stress in mice. The TST results
showed increase of immobility time of VEE-treated mice compared to both control groups. In 2017,
Razavi et al. reported the anti-anxiety and muscle relaxant effects of VEE and Vs in vivo [17]. Another
study showed induction of relaxation in mice and rats treated with essential oil extracted from the
aerial part of verbena [50]. Accordingly, the aqueous extract of this plant was found to have a sedative
effect in rats at high doses (700 and 1000 mg/Kg body weight of extract) [8]. Then, the increase of
immobility time observed in this study may suggest the relaxant and sedative effects of VEE.
The evaluation of the transcriptome in the collected brains showed an enhancement of expression
of genes implicated in the production of cAMP in the case of mice treated with VEE. Drd1 expression was
increased by VEE, while it remained stable in case of bupropion-treated mice. Previously, the enzymatic
activity of Ac was found to be tightly regulated by Drd1 through Gβα [32]. Also, VEE increased
the expression of Ac in mice brains, the enzyme that was down-regulated by Bupropion treatment.
Over-expression and activation of Ac by VEE implies an increase of cAMP generation, which has been
associated with the induction of relaxation effect [52]. Accordingly, the use of apomorphine, a Drd1
agonist, was proved to induce relaxation [53]. Moreover, treatment with the plant extract increased
Prkg1 expression, a gene that has been associated with induction of relaxation [28].
VEE affected the expression of genes modulating calcium homeostasis. Itpr2 is one of the
intracellular Ca2+ release channels, located in the membranes of endoplasmic and sarcoplasmic
reticula. These are organelles are rich in Ca2+ion [25]. VEE up-regulated the expression of Itpr2,
implicating an elevation of the ion in the cytosolic compartment. Ca2+-cytosolic content depends
also on channels facilitating the transport of ion from the extracellular compartment [54]. One of
these channels is Cacna1c which has been over expressed in VEE-treated mice. A previous study
evaluated the transcriptomic changes induced by relaxation in humans and Cacna1c was found
to by over-expressed [54]. Ca2+-induced increase by VEE, up-regulated the expression of Pkc, an
enzyme found to be dependent to Ca2+ concentration in cells, and which activates Ac inducing an
over-production of cAMP [41,55]. On the other hand, calcium homeostasis has been already proved
to play an important role in muscle movement and walking behavior in humans. At the brain level,
the calcium signaling regulates different functions, including signal transmission and also the learning
and memory [56–60]. When accumulated in cytoplasm, the calcium is transported into mitochondria
inducing the activation of enzymes implicated in generation of ATP, including ATP synthase and
NADH+ dehydrogenase [61]. The inhibition of the calcium uptake by the mitochondria was found
to increase the time needed for relaxation [62]. Accordingly, an increase of Ca2+ content has been
proved to induce ATP production through cAMP generation [63]. These results suggest that VEE
has a relaxant effect on mice through the generation of cAMP, which in addition to high intracellular
Ca2+levels, induces activation of mitochondria.
For VEE-treated mice, Gsn, Ttr, and Camk2n1 showed the highest expression levels compared to
the set of genes analyzed by microarray, and the increase was more than 2 fold-changes, while mice
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receiving Bupropion showed a decrease of Ttr expression, whereas Gsn and Camk2n1 expressions
were slightly increased (less than 1.5 fold-change). Mutant mice over-expressing Gsn revealed an
enhancement of respiratory chain activity [33]. Several studies have demonstrated the neuroprotective
role of Ttr [64–68], and its positive correlation to mitochondrial function [34]. These findings proved an
increase of mitochondrial activity, implying an over-production of ATP. VEE-treated group presented
high level of Camk2n1 expression compared to control group, which implicates a controlled cell
proliferation. Previously, a study demonstrated the tumor suppressive effect of Camk2n1 [35].
Pmch and Mchr1 were significantly down-regulated by VEE. Pmch-deficient mice, as well as
Mchr1-deficient mice, were found to be more active than wild type mice, and showing an increase in
metabolic rate [36,38]. A specific Mchr1 antagonist has showed antidepressant and anxiolytic effect [37].
The increase of immobility time of VEE-treated mice is due to the relaxant effect of the plant extract,
and the molecular analysis proved its antidepressant effect.
In order to evaluate the effect of lower doses of VEE and their respective Vs contents, a second
TST was conducted. The treatments used were 25 and 50 mg/Kg of VEE and 2.5 and 5 mg/Kg of
Vs. Interestingly, the results showed a decrease in immobility time compared to the control group,
and scores were statistically comparable to bupropion treated mice. Our findings suggest low doses
have an antidepressant effect. In accordance with the transcriptomic analysis conducted here above,
VEE and Vs might be induced mitochondrial activation through accumulation of cAMP and Ca2+,
to a lesser extent than high dose of VEE, resulting in agitation of mice rather than their relaxation.
To prove the antidepressant effect observed in vivo, we evaluated the levels of different depression
markers. Sert and NA implication in depression has been documented and are considered as targets
of antidepressants [47,48]. In our study, VEE and Vs were found to enhance Sert and NA levels
demonstrating an antidepressant effect of the treatments on mice.
Previous studies found that antidepressants targeting the expressions of Sert and NA only
present limitations. Patients might show movement delay, lack of concentration or even persistence
of anhedonia [69]. Accordingly, drugs acting on the dopaminergic system have been developed.
Dopamine is a catecholamine responsible of expression of emotions such as pleasure and motivation,
and stimulates concentration [69]. Hence, we assessed dopamine levels in brains. The results showed
a highly significant increase of dopamine expression by VEE and Vs compared to control group. These
findings prove the antidepressant activity of VEE and Vs by stimulating the pleasure mechanism.
It has been documented that antidepressants acting on serotonergic and norepinephric mechanisms
lead to enhancement of BDNF levels in rodents [70,71]. We evaluated the effect of treatments on BDNF
in brains. The results showed a highly significant increase of BDNF by VEE and Vs treatments. Also, it
has been documented that Ca2+ and cAMP levels regulate BDNF expression through CREB (cAMP
response element-binding protein) [72].
The results obtained in vivo revealed the activation of mechanisms responsible for the increase
of cytosolic Ca2+ and cAMP generation, messengers inducing the mitochondrial activity. To
confirm this hypothesis, we evaluated the effect of VEE on mitochondrial activity. The results
showed enhancement of mitochondrial function in a concentration-dependent manner. Accordingly,
Vs increased mitochondrial function in a similar tendency as VEE.ATP production in vitro was evaluated
to confirm the effect of VEE and Vs mitochondrial activity. Human neurotypicSH-SY5Y cells treated
with VEE showed a significant increase of ATP content in a dose-dependent manner after12h treatment.
Energy metabolism gradually decreased to regain the initial state. Vs is one of the most important
compounds contained in VEE, and has been proven to induce muscle relaxation in mice [17]. Next,
we evaluated the potential effect of Vs on mitochondrial activity. We observed that Vs-treatment also
showed an increase in ATP production at 12h, which restored to its original condition progressively.
In 2013, Bhasin et al. evaluated the transcriptomic changes in humans in response to relaxation
condition and showed regulation of genes activating energy metabolism [54]. ATP increase has been
found to be regulated positively by activation of mitochondrial calcium uptake, as aresult of different
stimuli such as alimentation, hormones and neurotransmitters [61,73–76]. Our in vitro study showed
Int. J. Mol. Sci. 2019, 20, 3556 12 of 19
that VEE and Vs enhanced intracellular calcium levels in a concentration and time-dependent manner
with similar tendency as mitochondrial activation. These results proved the increase of calcium and
energy metabolism related genes regulated by the treatments in vivo.
4. Materials and Methods
4.1. Plant Material and Extraction Method
The leaves of Lippia citriodora were collected in July 2016 from Marrakech Region (Morocco).
The species was authenticated by Prof. Ahmed Ouhammou from Cadi Ayyad University, Faculty of
Sciences Semlalia, Department of Biology, Marrakech, Morocco. A voucher specimen of plant material
(MARK-11186) was deposited in the Herbarium of the same institution. After air drying, the plant
material was crushed by a mortar and extracted with ethanol 70%, with a ratio plant material/solvent
of 10% (w/v). The extraction was carried out in the dark for 2 weeks and vigorously shacked twice a day.
The extract was centrifuged and the supernatant filtered through 0.22 µm Millipore (Mark Millipore,
Carrigtwohill, Ireland) and solvent evaporated by a rotary evaporator. The yield of VEE was 13.3%.
4.2. Chemicals
Vs, Hs and Vn were purchased from Sigma Aldrich, USA. Dulbecco’s Modified Eagle Medium
(DMEM)/F-12 and Opti-MEM were obtained from Gibco, USA. Fetal bovine serum was from Gibco,
South America. Penicillin - Streptomycin were purchased from Biowhittaker, USA. Non-essential amino
acids were from Cosmo Bio Co, LTD, Japan. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) and dexamethasone were from Dojindo, Japan. Bupropion was from Wako, Japan.
ATP bioluminescence kit was from TOYO Ink, Japan. ISOGEN kit was purchased from Nippon
Gene, Japan. RIPA lysis buffer was from (Santa Cruz Biotechnology, USA). 2-D Quant was purchased
from GE Healthcare Life Sciences, USA. Calcium Kit II-Fluo 4 was from Dojindo, Japan.
4.3. Cell Culture
The in vitro experiments were conducted on SH-SY5Y cells. This neurotypic cell line was obtained
from America Type Culture Collection, Manassas, USA. Cells were maintained in Dulbecco’s Modified
Eagle Medium (DMEM)/F-12, supplemented with 15% fetal bovine serum, 1% Penicillin (5000 µg/mL)
Streptomycin (5000 IU/mL) and 1% of non-essential amino acids. The culture was incubated at 37 ◦C
in a humidified atmosphere of 5% CO2 incubator. Opti-MEM, a reduced serum medium, was used to
culture cells for the evaluation of cell viability and intracellular ATP.
4.4. Determination of Cell Viability
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess cell
viability of SH-SY5Y cells. Briefly, the cells were seeded in a 96-well plate (fibronectin-coated plate)
(BD BioCoat, New York City, NY, USA) with a density of 2 × 105 cell/mL. After 24 h, the medium was
removed and the cells were VEE (0.5, 1, 2.5 and 5 µg/mL), Vs, Hs or Vn (3.1, 31.2 and 62.4 µg/mL) diluted
in Opti-MEM. After 72h incubation period, 10 µL MTT (5 mg/mL) mixed with 100 µL of Opti-MEM
was added to each well and the plate was incubated for further 6 h. The formazan crystals formed by
the mitochondrial activity were solubilized by adding 100 µL of 10 % SDS (w/v). The absorbance was
measured at 570 nm using a microtiter plate reader (Dainippon Sumitomo Pharma Co., Ltd., Tokyo,
Japan). The results were expressed in percentage of relative cell viability.
To evaluate the neuroprotective effect of VEE, Vs, Hs and Vn, the cells were co-treated with DEX
(50 µM), incubated for 72h, then their viability assessed by MTT assay as described above.
4.5. Animals
Male ICR mice, 3 weeks old, weighting between 20 and 30 g were purchased from Charles River
laboratories (Tokyo, Japan). Mice were housed individually and had access to food and water ad libitum,
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in a controlled environment (56% humidity, 23 ◦C temperature, 12/12 h light/dark cycle). Before starting
the oral administration and the tail suspension test, the mice were allowed to acclimatize for one week.
All experiments were performed in strict accordance with NIH guidelines and were approved by the
Animal Ethics Committee of the University of Tsukuba, Japan. The ethical approval code is 16-042
(1/06/2016).
4.6. Tail Suspension Test
The animals were divided into three groups. A negative control group receiving Milli-Q water
(10 mL/Kg; n = 6), a positive control group treated with 20 mg/Kg of Bupropion (n = 7) and VEE-treated
group (n = 7) which received a dose of 100 mg/Kg. The samples were administrated orally every day
for 7 days.
The tail suspension test (TST) is a widely used technique to screen the antidepressant effects of
drugs. The methodology used in this study is as described by Steru et al., 1985 [77]. Briefly, the TST
was performed 60 min after the administration of treatments. The duration of the test was 6 min and
the immobility time was measured on the last 4 min of the test. A mouse was considered immobile only
when it is hanged passively, showing no resistance to the stress applied by the test. The experiment
was recorded using a camera and scored by observing the videos. After completion of the behavioral
test, mice were sacrificed by cerebrospinal dislocation, then the whole brains were collected for the
subsequent analysis.
A second TST was conducted to evaluate the effect of lower doses of VEE (25 mg/Kg, n = 6;
50 mg/Kg, n = 7) and their respective Vs content (2.5 mg/Kg, n = 6; 5 mg/Kg body weight, n = 7) on mice.
HPLC analysis showed that VEE contains 10% of Vs (data not shown). Other control groups (Milli-Q,
n = 6; Bupropion 20 mg/mL, n = 7) were used for the second test. TST was performed according to the
protocol previously described.
4.7. DNA Microarray Analysis
The total RNA was extracted from the brain tissues previously collected using ISOGEN kit and
quantified by Nanodrop 2000 spectrophotometer (Thermo Fisher scientific, Wilmington, NC, USA).
To elucidate the molecular mechanism underlying the effect of VEE on neuronal activities, we
evaluated the total gene expression of brain tissues by performing microarray on RNAs previously
extracted. The experiment was conducted according to the Affymetrix Genechip 3’ IVT PLUS reagent
kit user’s guide. Briefly, the RNAs were reverse transcripted to generate double stranded DNA.
The latter used as a template to synthesize the Biotin-labeled cRNA. After fragmentation of the labeled
cRNA, the mixture was hybridized to the Affymetrix mouse 430 PM array strips (Affymetrix) for 16 h
at 45 ◦C in the hybridization station. In Geneatlas Fluidics station, the hybridized arrays were washed
and stained, then scanned using Geneatlas imaging station. The total number of genes analyzed
by this method is 39,396 genes. All brain samples were analyzed by microarray. The data obtained
were analyzed by Expression Console and Pathway Studio software and DAVID and Consensus
Path databases.
4.8. Real Time Polymerase Chain Reaction (qRT-PCR)
RNA extracts obtained from mice brains were used as templates to validate the microarray results
through evaluation of the expression level of some relevant genes regulated by Verbena treatment. First,
a reverse transcription was performed, using the Superscript IV reverse transcriptase kit (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s protocol. Briefly, we incubated a mixture of RNA
samples (0.2 µg/µL) and Oligo(dT)12-18/dNTP (0.5 µg/µL; 10 mM) for 5 min at 65 ◦C, and then placed for
1 min on ice. The Reverse transcriptase solution was added and incubated the samples at 42 ◦C for 60
min and then 10 min at 60 ◦C. The cDNA produced is used to evaluate the expression of 3 genes: Gelsolin
“Gsn” (Mm00456679_m1), Transthyretin “Ttr” (Mm00443267_m1), Calcium/calmodulin-dependent protein
kinase II inhibitor 1 “Camk2n1” (Mm01718432_s1) and Inositol 1,4,5-trisphosphate receptor type 2 “Itpr2”
Int. J. Mol. Sci. 2019, 20, 3556 14 of 19
(Mm00444937_m1). This experiment was conducted using TaqMan Universal PCR mix and TaqMan
Probes and the amplifications were performed in a 7500 Fast Real-time PCR (Applied Biosystems,
Foster City, CA, USA) with the following conditions: 50 ◦C for 2 min, followed by 95 ◦C for 10 min,
and 40 cycles of 95 ◦C for 15 s followed by 60 ◦C for 1 min.
4.9. Quantification of Neurotransmitters and BDNF
To confirm the antidepressant effect of VEE and Vs at lower doses, we quantified the levels of
serotonin (Sert), noradrenaline (NA), dopamine and BDNF in brains. The proteins were measured in
the frontal cortex. First we homogenized 100 mg of tissue in 1 mL of RIPA buffer. The homogenate
was centrifuged for 5 min at 10,000× g and 4 ◦C. The supernatant was collected and stored at −80 ◦C.
The dopamine, Sert and NA were quantified using ELISA kits (Immusmol SAS, Talence, France). BDNF
was measured by colorimetric sandwich ELISA kit (Proteintech, Rosemont, IL, USA). The experiments
were conducted following the manufacturer’s instructions. The results of each treatment group were
corrected by their respective total protein content determined using 2-D Quanti kit.
4.10. Measurement of Mitochondrial Activity
Mitochondrial function was measured using rhodamine 123, a fluorescent dye. The protocol was
as described previously by Matsukawa et al., 2017 [78]. Briefly, treated SH-SY5Y were incubated for
20 min at 37 ◦C after addition of rhodamine 123 (10 µg/mL). Cells were lysed by 1% Triton X-100 and
the fluorescence intensity of rhodamine (excitation/emission 485/528 nm) was measured.
4.11. Measurement of the Intracellular ATP Production
The mitochondrial activity was assessed by measuring the intracellular ATP content of cells using
ATP bioluminescence kit. Cells were cultured (2 × 105 cell/mL) in a 96-well plate (fibronectin-coated
plate) and treated with different concentrations of VEE and Vs for 6, 12, 24, 48 and 72 h. The cells were
lysed and the ATP content measured by adding 100µL of luciferin-luciferase solution. The luminescence
was measured using the microtiter plate reader (Dainippon Sumitomo Pharma Co., Ltd., Japan).
4.12. Measurement of Intracellular Calcium Level
Calcium Kit II-Fluo 4 was used to measure intracellular calcium levels of SH-SY5Y.
The measurement was conducted according to the manufacturer’s protocol. Briefly, SH-SY5Y cells
were seeded in black clear-bottom 96 well plates (Corning, NY, USA) and then treated with loading
buffer (5% Pluronic F-127, 250-mmol/L Probenecid and 1-µg/µLFluo 4 AM in Hanks’–HEPES Buffer)
for 1 h. The supernatant was removed and cells were washed with PBS. Cells were treated with VEE
and Vs as described previously. Fluorescence intensity (excitation/emission 485/528 nm) was measured
every 30 min using a Powerscan HT plate reader.
4.13. Statistical Analysis
Results are expressed as means ± SD, and statistical analyses were performed using a Student’s
t-test using IBM SPSS Statistics 23 software. Differences were determined statistically significant at a
P-value of less than 0.05.
5. Conclusions
Taken together, our findings suggest that, depending on the administered dose, VEE and Vs
induce either relaxation or anti-depression effects. Higher doses of VEE induced relaxation through
regulation of genes, including Itpr2 and Ac, responsible for Ca2+ and cAMP generation. Lower doses of
VEE and their respective Vs amount treatments was found to induce antidepressant-like effects by
enhancing the BDNF, NA, Sert and dopamine expressions, which are cAMP and Ca2+ dependent. VEE
Int. J. Mol. Sci. 2019, 20, 3556 15 of 19
and Vs increased Ca2+ intracellular levels leading to the enhancement of mitochondrial activity and
ATP concentration. The effects of VEE observed in vivo and in vitro are due mostly to Vs.
Author Contributions: Conceptualization, M.S., K.S., C.G. and H.I.; Data curation, M.S. and K.S.; Formal analysis,
M.S.; Funding acquisition, H.I.; Investigation, M.S.; Methodology, M.S., K.S. and H.I.; Project administration, H.I.;
Resources, H.I.; Software, M.S.; Supervision, K.S. and H.I.; Validation, M.S., K.S. and H.I.; Visualization, M.S.;
Writing—original draft, M.S.; Writing—review & editing, K.S., C.G. and H.I.
Funding: This research was funded by SCIENCE AND TECHNOLOGY RESEARCH PARTNERSHIP FOR
SUSTAINABLE DEVELOPMENT (SATREPS), grant number JPMJSA1506.
Acknowledgments: Ministry of Education, Culture, Sports, Science and Technology (MEXT) for funding this
work partially.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
Ac Adenylate cyclase
Adora2 Adenosine A2a receptor
Cacna1c Calcium channel, voltage-dependent, L type, alpha 1C subunit
Camk2n1 Calcium/calmodulin-dependent protein kinase II inhibitor 1
Camk4 Calcium/calmodulin-dependent protein kinase IV
Dex Dexamethasone
Drd1 Dopamine receptor 1
Gsn Gelsolin
Hs Hastatoside
Htr4 5 hydroxytryptamine (serotonin) receptor 4
Itpr2 Inositol 1,4,5-trisphosphate receptor type 2
Mchr1 Melanin-concentrating hormone receptor
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NA Noradrenaline
Pkc Protein kinase c
Pmch Pro-melanin-concentrating hormone
Prkg1 cGMP-dependent protein kinase 1
Sert Serotonin
TST Tail suspension test
Ttr Transthyretin
VEE Verbena ethanolic extract
Vn Verbenalin
Vs Verbascoside
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